Becton Dickinson earnings missed by $1.55, revenue topped estimates
Becton Dickinson (BDX) reported Q4 EPS of $2.52, missing estimates by $1.55, but revenue of $5.3B topped expectations. The company guided FY 2027 EPS to $13.10-$13.30, above consensus. BDX stock is up 18.28% in 3 months and 50.06% in 12 months.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance downgrade are likely to trigger short‑term selling pressure, though the revenue beat offers a modest positive note.
Market read
First‑time earnings disclosure for a large‑cap health‑care stock; material impact on BDX and potential spillover to sector peers.
What to watch
Potential upside from upcoming product launches and long‑term contracts not reflected in the short‑term earnings miss.
Background
Becton Dickinson (BDX) reported Q4 results with EPS below expectations and provided FY2027 guidance below consensus, while revenue slightly beat estimates.
Ticker impact
Q4 EPS missed estimate by $1.55 and FY2027 guidance lowered to $13.10-$13.30, a fresh earnings disclosure.
likely downside as market prices in the EPS miss and reduced guidance
The EPS miss is material and the guidance range is below consensus, which typically triggers sell pressure for a large-cap medical device company.
Market effects
May weigh on other medical‑device peers as earnings expectations tighten.
U.S. healthcare sector could see modest pullback in the afternoon session.
Limited; primarily a U.S. equity impact.
Counterpoint
Revenue beat and strong cash flow could support a bounce if investors focus on top‑line strength.
Key entities
- companyBecton Dickinson
Medical‑device and diagnostics manufacturer (NYSE: BDX).
